E. Stein, M. Lane, and P. Laskarzewski, Comparison of Statins in Hypertriglyceridemia, The American Journal of Cardiology, vol.81, issue.4
DOI : 10.1016/S0002-9149(98)00041-1

L. Spieker, . Sudano-1, D. Hurlimann, P. Lerch, M. Lang et al., High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men, Circulation, vol.105, issue.12, pp.1399-402, 2002.
DOI : 10.1161/01.CIR.0000013424.28206.8F

F. Sacks, M. Pfeffer, L. Moye, J. Rouleau, J. Rutherford et al., The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial lnvestigators (CARE)

H. Colhoun, D. Betteridge, P. Durrington, G. Hitman, H. Neil et al., Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial, The Lancet, vol.364, issue.9435, pp.685-96, 2004.
DOI : 10.1016/S0140-6736(04)16895-5

R. Afssaps, Prise en charge thérapeutique du patient dyslipidémique. mars, 2005.

A. Castaigne and D. Pouchain, Statines: utilité et bon usage, Rev Prat, vol.19, pp.559-70, 2005.

O. Tl and M. D. Cpk, MedlinePlus Medical Encyclopedia

P. Kamoun, Créatine kinase sérique. Guide des examens de laboratoire. 4eme édition, pp.1372-1375, 2002.

T. Zenone, Interprétation d'une élévation de la créatine phosphokinase et de la lactate déshydrogénase

R. Jerry and J. Mendell, Démarche clinique devant une affectation musculaire

. Neurologues-du-groupe-pitié-salpêtrière, Neuropathologie DCEM2-DCEM3. 28 juin, 2000.

. Le-scandale-de-la-cérivastatine-de-bayer, les médicaments anti-cholestérol et la politique de santé publique. Pratiques -Les cahiers de la médecine utopique, 2003.

C. Naranjo, U. Busto, and E. Sellers, A method for estimating the probability of adverse drug reactions, Clinical Pharmacology and Therapeutics, vol.30, issue.2, pp.239-284, 1981.
DOI : 10.1038/clpt.1981.154

K. Holloway and T. Green, Les comités pharmaceutiques et thérapeutiques. Guide pratique, pp.56-77, 2005.

A. Ml-gras, V. Caron, and J. , Atteintes musculaires sévères sous statines: bilan des cas notifiés en France jusqu'à fin février 2002 et données concernant les risques liés a la cerivastatine, Therapie, vol.60, pp.299-304, 2005.

D. Waters, Safety of High-Dose Atorvastatin Therapy, The American Journal of Cardiology, vol.96, issue.5
DOI : 10.1016/j.amjcard.2005.06.028

B. Eriksson-ml-angelin and S. Sjoberg, Risk for fatal statin-induced rhabdomyolysis as a consequence of misinterpretation of 'evidence-based medicine', Journal of Internal Medicine, vol.14, issue.3, pp.313-317, 2005.
DOI : 10.1016/S0195-668X(03)00347-6

J. Sochman and M. Podzimkova, Not al1 statins are alike: induced rhabdomyolysis on changing from one statin to another one

M. Ho, J. Baker, and A. Miller, Simvastatin-induced rhabdomyolysis, The American Journal of Emergency Medicine, vol.22, issue.3
DOI : 10.1016/j.ajem.2004.02.023

A. Fauchais, I. Ba, B. Maurage, P. Kyndtt, X. Bataille-dl-hachulla et al., Polymyosites induites ou associ??es aux traitements hypolip??miants???, La Revue de M??decine Interne, vol.25, issue.4, pp.294-302, 2004.
DOI : 10.1016/j.revmed.2003.10.013

P. Zuech, P. Cl-duthoit-cl-mery, L. Somogyi, A. Louboutin, A. Veyssier-belot et al., Dermatomyosite induite par la pravastatine, La Revue de M??decine Interne, vol.26, issue.11, pp.897-902, 2005.
DOI : 10.1016/j.revmed.2005.07.005

O. Vasconcelos and W. Campbell, Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake, Muscle & Nerve, vol.73, issue.6, pp.803-810, 2004.
DOI : 10.1097/00007611-198007000-00016

A. Kashani, C. Phillips, J. Foody, Y. Wang, S. Mangalmurti et al., Risks associated with statin therapy.A systematic overview of randomized clinical trials, Circulation, vol.1, issue.14, pp.2788-97, 2006.

R. Pasternak, S. Smith, S. Bairey-mertz-cl-grundy, J. Cleeman, and C. Lenfant, American College of Cardiology: American Heart Association: National Heart Lung and Blood Institute. ACCIAHAINHLBI Clinical advisory on the use and safety of statins, Circulation, vol.106, pp.1024-1032, 2002.

C. Hodel, Myopathy and rhabdomyolysis with lipid-lowering drugs, Toxicology Letters, vol.128, issue.1-3, pp.1-59, 2002.
DOI : 10.1016/S0378-4274(02)00010-3

S. Gambelli, M. Dotti, A. Malandrini, M. M. Stromillo, M. Federico et al., Mitochondrial alterations in muscle biopsies of patients on statin therapy, J Submicrosc Cytol, vol.36, pp.85-94, 2004.

S. Baker, Molecular clues into the pathogenesis of statin-mediated muscle toxicity, Muscle & Nerve, vol.65, issue.5, pp.572-80, 2005.
DOI : 10.1016/S0304-4165(01)00190-8

L. Ernster and G. Dallner, Biochemical, physiological and medical aspects of ubiquinone function, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol.1271, issue.1, pp.195-204, 1995.
DOI : 10.1016/0925-4439(95)00028-3

S. Matzno, S. Yasuda, S. Juman, Y. Yamamoto, N. Nagareya-lshida et al., Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein, Journal of Pharmacy and Pharmacology, vol.92, issue.11
DOI : 10.1016/S0163-7258(01)00159-0

B. Noel, Autoimmune disease and other potential side-effects of statins, The Lancet, vol.363, issue.9425, 2000.
DOI : 10.1016/S0140-6736(04)16423-4

B. Noel, Regarding the mechanism of statin-induced myopathy, American Heart Journal, vol.149, issue.2, p.3, 2005.
DOI : 10.1016/j.ahj.2004.08.020

L. Rudski, M. Rabinovitch, and D. Danoff, Systemic Immune Reactions to HMG-CoA Reductase Inhibitors: Report of 4 Cases and Review of the Literature, Medicine, vol.77, issue.6, pp.378-83, 1998.
DOI : 10.1097/00005792-199811000-00002

J. Kobashigawa, Statins and Cardiac Allograft Vasculopathy after Heart Transplantation, Seminars in Vascular Medicine, vol.4, issue.04, pp.401-407, 2004.
DOI : 10.1055/s-2004-869597

G. Weitz-schmidt, K. Welzenbach, and V. Brinkmann, Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site, Nature Medicine, vol.270, issue.6, pp.687-92, 2001.
DOI : 10.1074/jbc.270.21.12531

. Kwak-6, F. Mulhaupt, S. Myit, and F. Mach, Statins as a newly recognized type of immunomodulator, Nature Medicine, vol.165, issue.12, pp.1399-402, 2000.
DOI : 10.4049/jimmunol.165.3.1285

N. Nath, S. Giri, R. Prasad, and A. Singh, Singh 1. Potental targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy, J, vol.172, pp.1273-86, 2004.

V. Needham-ml-fabian, W. Knezevic, P. Panegyres, Z. Pl-mastaglia, and F. , Progressive myopathy with up-regulation of MHC-I associated with statin therapy, Neuromuscular Disorders, vol.17, issue.2, pp.194-200, 2007.
DOI : 10.1016/j.nmd.2006.10.007

A. Draeger, K. Monastyrskaya, M. Mohaupt, H. Hoppeler, H. Savolainen et al., Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia, The Journal of Pathology, vol.555, issue.1, pp.94-95, 2006.
DOI : 10.1002/j.1552-4604.1993.tb03948.x

N. Wahl-dl-petitpain, M. Frederic, S. Bour, and P. Trechot, Myopathy associated with statin therapy, Neuromuscular Disorders, vol.17, issue.8, pp.661-663, 2007.
DOI : 10.1016/j.nmd.2007.04.001